ClinicalTrials.gg
CompletedNCT05432167Updated May 20, 2025Results posted

A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

A Phase 2 interventional study of CIN-107 and Placebo in Uncontrolled Hypertension and Chronic Kidney Diseases, sponsored by AstraZeneca. Completed at 71 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.

Enrollment
17th of 38
195 · median 170
Started
2022
with 8 others
Phase 2
9 of 54
none open now
Registered
29th of 54
by date

Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 17th largest by enrollment of the 38 interventional ones that give a count, is one of 9 that started in 2022, is one of 9 in phase 2, and was the 29th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Renal Insufficiency, Chronic by AstraZeneca, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).

Read the detailed description

This randomized, double-blind, placebo-controlled will evaluate the efficacy and safety of CIN-107 in patients with uHTN and CKD. Approximately 200 patients will be randomized in a 1:1:1 ratio into 1 of the 3 treatment groups (placebo, low dose treatment strategy and high dose treatment strategy).

The study will consist of the following 3 periods:

  • A Screening Period of up to 5 weeks;
  • A Double-Blind Treatment Period of 26 weeks; and
  • A Follow-Up Period of 2 weeks.

Patients will complete the study in approximately 8 months.

03

Conditions studied

  • Uncontrolled Hypertension
  • Chronic Kidney Diseases
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a mean seated SBP ≥ 140 mmHg.
  • Has a prior diagnosis of mild-to-severe CKD.
  • Has an elevated UACR.
  • Is currently taking an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) at the maximum tolerated daily dose.

Exclusion criteria

Exclusion Criteria:

  • Have a documented diagnosis of type 1 diabetes.
  • Are not willing or not able to discontinue a mineralocorticoid receptor antagonist (MRA) or a potassium sparing diuretic as part of an existing antihypertensive regimen.
  • Have a single occurrence of mean seated SBP >180 mmHg or DBP >110 mmHg during the Screening Period.
  • Has a (BMI) >50 kg/m\^2.
  • Has documented bilateral renal artery stenosis of ≥70%.
  • Has had dialysis for acute kidney injury/acute renal failure within 12 weeks prior to the Screening Period or has a planned dialysis or kidney transplantation during the course of the study.
  • Has known documented chronic heart failure Class III or Class IV and/or hospitalization for heart failure within 6 months of Screening.
  • Has had a stroke, , hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months of Screening.
  • Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease.
  • Has planned any major cardiac surgery during the study or had major cardiac surgery within 6 months of Screening.
  • Has had a prior solid organ transplant or cell transplant.
  • Has a known to CIN-107 or drugs of the same class
  • Has received immunotherapy for treatment of CKD within 6 months of Screening.
  • Has any clinically relevant medical or surgical conditions including unstable conditions and/or conditions requiring regular transfusion or treatment with systemic , including .
  • Serum potassium \<3.5 mEq/L or >5.0 mEq/L
  • Serum sodium \<135 mEq/L
  • Serum or alanine aminotransferase >3 × (ULN); or Total >2 × ULN, unless due to Gilbert's syndrome.
  • is \< 25 or > 75 mL/min/1.73 m2
  • Has uncontrolled diabetes with glycosylated >10.5%.
  • Is positive for Human immunodeficiency disease () antibody, surface antigen, or virus Ribonucleic acid (RNA).
  • Has typical consumption of >14 alcoholic drinks weekly.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    Low dose CIN-107

    Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.

    Drug: CIN-107

  • Experimental
    High dose CIN-107

    Patients will take oral tablets of CIN-107 for 26 weeks. The dose strength may be titrated within 6 weeks.

    Drug: CIN-107

  • Placebo comparator
    Placebo

    Patients will take oral tablets of Placebo for 26 weeks. The dose strength may be titrated within 6 weeks.

    Drug: Placebo

Interventions

  • Patients will take CIN-107 tablets by mouth once daily.

  • DrugPlacebo

    Patients will take placebo tablets by mouth once daily.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo

    Mean change in seated SBP from baseline to Week 26 of pooled CIN-107 and placebo was assessed.

    Time frame: At Week 26

Secondary outcomes

  1. Change From Baseline in SBP in CIN-107 Compared to Placebo in Participants Assigned to the High-dose Strategy Group

    Mean change in seated SBP from baseline to Week 26 of high-dose CIN-107 dosing group and placebo was assessed.

    Time frame: At Week 26

  2. Change From Baseline of SBP in CIN-107 Compared to Placebo in Participants Assigned to the Low-dose Strategy Group

    The mean change in seated SBP from baseline to Week 26 of low-dose CIN-107 dosing group and placebo was assessed.

    Time frame: At Week 26

Other outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    The safety and tolerability of CIN-107 in participants with uncontrolled hypertension (uHTN) and chronic kidney disease (CKD) was assessed. Adverse events of special interest (AESI) include any hypotension events, abnormal potassium or sodium laboratory values that require clinical intervention.

    Time frame: From randomization (Day 1) until the end of Follow up period (approximately 8 months)

07

Results

Posted May 20, 2025

Participant flow

This study was conducted from 29 April 2022 to 02 May 2024 at 78 sites in the United States.

Participant flow — Overall Study
MilestoneCIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlacebo
Started656466
Completed535451
Not completed121015
Withdrew: Adverse event021
Withdrew: Lost to follow-up332
Withdrew: Inclusion/exclusion criteria not met110
Withdrew: Physician decision100
Withdrew: Withdrawal by subject7411
Withdrew: Other001

Outcome measures

PrimaryChange From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo

Mean change in seated SBP from baseline to Week 26 of pooled CIN-107 and placebo was assessed.

Time frame:
At Week 26
Reported as:
Least squares mean · Millimeters of mercury (mmHg)
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo
Millimeters of mercury (mmHg)CIN-107 Treatment Groups PooledPlacebo
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo-15.22 ± 1.532-7.15 ± 2.231
Statistical analysis
  • CIN-107 Treatment Groups Pooled vs Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -8.08 · 95% CI -13.36 to -2.79
SecondaryChange From Baseline in SBP in CIN-107 Compared to Placebo in Participants Assigned to the High-dose Strategy Group

Mean change in seated SBP from baseline to Week 26 of high-dose CIN-107 dosing group and placebo was assessed.

Time frame:
At Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in SBP in CIN-107 Compared to Placebo in Participants Assigned to the High-dose Strategy Group
mmHgCIN-107 High Dosing Strategy GroupPlacebo
Change From Baseline in SBP in CIN-107 Compared to Placebo in Participants Assigned to the High-dose Strategy Group-14.37 ± 2.117-7.16 ± 2.233
Statistical analysis
  • CIN-107 High Dosing Strategy Group vs Placebo · Mixed Models Analysis · p = 0.019 · Mean difference (final values): -7.22 · 95% CI -13.24 to -1.19
SecondaryChange From Baseline of SBP in CIN-107 Compared to Placebo in Participants Assigned to the Low-dose Strategy Group

The mean change in seated SBP from baseline to Week 26 of low-dose CIN-107 dosing group and placebo was assessed.

Time frame:
At Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline of SBP in CIN-107 Compared to Placebo in Participants Assigned to the Low-dose Strategy Group
mmHgCIN-107 Low Dosing Strategy GroupPlacebo
Change From Baseline of SBP in CIN-107 Compared to Placebo in Participants Assigned to the Low-dose Strategy Group-16.14 ± 2.186-7.16 ± 2.233
Statistical analysis
  • CIN-107 Low Dosing Strategy Group vs Placebo · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -8.99 · 95% CI -15.10 to -2.87
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

The safety and tolerability of CIN-107 in participants with uncontrolled hypertension (uHTN) and chronic kidney disease (CKD) was assessed. Adverse events of special interest (AESI) include any hypotension events, abnormal potassium or sodium laboratory values that require clinical intervention.

Time frame:
From randomization (Day 1) until the end of Follow up period (approximately 8 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsCIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlacebo
All TEAEs485235
All TEAEs, related to treatment233114
Any TEAE with outcome = Death000
Any TEAE with outcome = Death, related to treatment000
Any TEAE leading to dose interruption202313
Any TEAE leading to dose interruption, related to treatment10104
Any TEAE leading to discontinuation of treatment10115
Any TEAE leading to discontinuation of treatment, related to treatment783
Any TEAE leading to discontinuation of study021
Any TEAE leading to discontinuation of study, related to treatment011
All treatment emergent serious adverse events (TESAEs)752
All TESAEs, related to treatment211
Any TESAE with outcome = Death000
Any TESAE with outcome = Death, related to treatment000
Any TESAE leading to dose interruption211
Any TESAE leading to dose interruption, related to treatment001
Any TESAE leading to discontinuation of treatment221
Any TESAE leading to discontinuation of treatment, related to treatment210
Any TESAE leading to discontinuation of study010
Any TESAE leading to discontinuation of study, related to treatment000
Treatment emergent AESIs11124

Adverse events

Collected over From randomization (Day 1) until the end of Follow up period (approximately 8 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CIN-107 Low Dosing Strategy Group0/65 (0%)7/65 (10.8%)47/65 (72.3%)
CIN-107 High Dosing Strategy Group0/63 (0%)5/63 (7.9%)52/63 (82.5%)
Placebo0/64 (0%)2/64 (3.1%)35/64 (54.7%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlacebo
Acute kidney injuryRenal and urinary disorders3/650/630/64
HyperkalaemiaMetabolism and nutrition disorders2/651/630/64
Eye infectionInfections and infestations0/651/630/64
Nodal arrhythmiaCardiac disorders0/651/630/64
Deep vein thrombosisVascular disorders0/651/630/64
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/651/630/64
HaemorrhoidsGastrointestinal disorders0/651/630/64
Lower gastrointestinal haemorrhageGastrointestinal disorders0/651/630/64
ProctalgiaGastrointestinal disorders0/651/630/64
Rectal haemorrhageGastrointestinal disorders0/651/630/64
Most frequent other events
Showing 10 of 147
Most frequent other events
EventCIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlacebo
HyperkalaemiaMetabolism and nutrition disorders21/6532/633/64
Blood creatinine increasedInvestigations11/6515/635/64
Renal impairmentRenal and urinary disorders2/655/633/64
Muscle spasmsMusculoskeletal and connective tissue disorders2/655/632/64
Glomerular filtration rate decreasedInvestigations2/654/635/64
Chronic kidney diseaseRenal and urinary disorders0/650/634/64
Orthostatic hypotensionVascular disorders2/652/634/64
HyponatraemiaMetabolism and nutrition disorders4/651/630/64
Blood potassium increasedInvestigations4/650/630/64
Lipase increasedInvestigations2/653/631/64

Baseline characteristics

Intent-to-treat population (ITT) included all participants randomized into the study. Treatment classification was based on the randomized treatment assignment.

Age, Continuous
Age, Continuous(Years)CIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlaceboTotal
Age67.2 ± 12.6366.5 ± 11.0265.6 ± 10.7966.4 ± 11.46
Sex: Female, Male
Sex: Female, Male(Participants)CIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlaceboTotal
Female23211963
Male424347132
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CIN-107 Low Dosing Strategy GroupCIN-107 High Dosing Strategy GroupPlaceboTotal
Race — Asian43512
Race — Black or African American19242063
Race — White413438113
Race — Other0123
Race — Not Reported1214
08

Study locations

71 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Los Angeles, California 90010, United States
  • Research Site
    Lynwood, California 90262, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Panorama City, California 91402, United States
  • Research Site
    Pomona, California 91767, United States
  • Research Site
    Rancho Cucamonga, California 91730, United States
  • Research Site
    Riverside, California 92503, United States
  • Research Site
    S. Gate, California 90280, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Vacaville, California 95687, United States
  • Research Site
    Victorville, California 92392, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Orlando, Florida 32807, United States
  • Research Site
    Orlando, Florida 32808, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Nampa, Idaho 83687, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Brownsburg, Indiana 46112, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Silver Spring, Maryland 20904, United States
  • Research Site
    New Bedford, Massachusetts 02740, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Flint, Michigan 48532, United States
  • Research Site
    Troy, Michigan 48085, United States
  • Research Site
    Olive Branch, Mississippi 38654, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Trenton, New Jersey 08611, United States
  • Research Site
    Bronx, New York 10455, United States
  • Research Site
    Durham, North Carolina 27704, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Kinston, North Carolina 28504, United States
  • Research Site
    Morganton, North Carolina 28655, United States
  • Research Site
    Oxford, North Carolina 27565, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Cincinnati, Ohio 45246, United States
  • Research Site
    Bethany, Oklahoma 73008, United States
  • Research Site
    Scottdale, Pennsylvania 15683, United States
  • Research Site
    Smithfield, Pennsylvania 15478, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    Paris, Texas 75462, United States
  • Research Site
    Red Oak, Texas 75154, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    San Antonio, Texas 78249, United States
  • Research Site
    Salt Lake City, Utah 84132, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Alexandria, Virginia 22304, United States
  • Research Site
    Burke, Virginia 22015, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Kingwood, West Virginia 26537, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in May 2024, 24 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 24 months is above that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2022
First posted
Jun 27, 2022
StartActual
Apr 29, 2022
Primary completionActual
May 2, 2024
CompletionActual
May 2, 2024
Results first posted
May 20, 2025
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05432167
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Apr 29, 2022
Primary completion
May 2, 2024
Completion
May 2, 2024
Results posted
May 20, 2025
Last update
May 20, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion